THERADIAG announced an agreement with Quotient Limited under which the two companies will partner to advance autoimmune diagnostics by leveraging Quotient's MosaiQ platform. Under the new agreement, Theradiag will supply Quotient with autoimmune reagents and multi-constituent quality controls, for the development of autoimmune microarrays to be used on the MosaiQ solution. The parties intend the first application covered by their new collaboration will be a solution for Connective Tissue Diseases (CTD).

CTD testing involves a complex diagnostic pathway which is based on the screening for Anti-Nuclear Antibodies (ANA) and tiered testing for Extractable Nuclear Antigen Antibodies (ENA), to identify the exact autoimmune disease. Quotient believes that the integration of several autoantibody tests into a single multiplexed assay has the potential to transform autoimmune disease testing and by doing so to accelerate diagnosis and therapy selection. Autoimmune diseases represent one of the leading global causes of morbidity.

Connective tissue autoimmune diseases are potentially severe, systemic medical conditions such as Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome, Systemic Scleroderma, Polymyositis/Dermatomyositis, and Mixed Connective Tissue Disease, often causing inflammation that may affect skin, joints, kidneys, blood cells, brain, heart and lungs, with clinical symptoms mimicking many other diseases. In the United States alone, it is estimated that 1.5 million Americans have a form of lupus, with an incidence of approximately 16,000 new cases per year, an annual total diagnosis and treatment cost per patient as high as $50,000, and six years on average to diagnosis. Quotient estimates that autoimmune diagnostics would provide an additional $2 billion addressable market opportunity for Quotient's MosaiQ platform.

Autoimmune IVD's are EU IVD Regulation class B or C and US FDA 510(k) regulated devices and typically provide a faster and lower cost path to market than blood transfusion and other high medical safety risk tests.